The bacterial second messenger cdiGMP exhibits promising activity as a mucosal adjuvant.
about
Evaluation of the sublingual route for administration of influenza H5N1 virosomes in combination with the bacterial second messenger c-di-GMPCyclic di-GMP: the first 25 years of a universal bacterial second messengerIntranasal vaccination with a plant-derived H5 HA vaccine protects mice and ferrets against highly pathogenic avian influenza virus challenge.Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model.A study of Chitosan and c-di-GMP as mucosal adjuvants for intranasal influenza H5N1 vaccine.Antibiotics in Canadian poultry productions and anticipated alternativesIntranasal delivery of influenza rNP adjuvanted with c-di-AMP induces strong humoral and cellular immune responses and provides protection against virus challenge.Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity.Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants.Leptospirosis vaccines.Needle-free vaccine delivery.Mucosal vaccination against bacterial respiratory infections.Cyclic di-nucleotides: new era for small molecules as adjuvants.Nucleotide, c-di-GMP, c-di-AMP, cGMP, cAMP, (p)ppGpp signaling in bacteria and implications in pathogenesis.Biofilm infections, their resilience to therapy and innovative treatment strategies.Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies.New Horizons in the Development of Novel Needle-Free Immunization Strategies to Increase Vaccination Efficacy.STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment.Inducing Mucosal IgA: A Challenge for Vaccine Adjuvants and Delivery Systems.Large-scale production of the immunomodulator c-di-GMP from GMP and ATP by an enzymatic cascade.Stimulation of innate immunity by in vivo cyclic di-GMP synthesis using adenovirus.Sublingual targeting of STING with 3'3'-cGAMP promotes systemic and mucosal immunity against anthrax toxins.cGAMP Promotes Germinal Center Formation and Production of IgA in Nasal-Associated Lymphoid Tissue.STING-Activating Adjuvants Elicit a Th17 Immune Response and Protect against Mycobacterium tuberculosis Infection.Enhanced immunostimulatory activity of cyclic dinucleotides on mouse cells when complexed with a cell-penetrating peptide or combined with CpG.STING agonists enable antiviral cross-talk between human cells and confer protection against genital herpes in mice.
P2860
Q21090975-134987C1-B0FE-498D-B089-013D282FCB84Q26850396-90325213-AF8E-4A99-AE34-25D34D692BF3Q30372105-41DC785C-DE5C-4BB5-9AA6-67F3C6051021Q30403760-1735FA98-94D0-424E-B929-E962A992E5EFQ30423922-D1970AD4-5800-45A7-B979-E2C656410ABCQ33767070-EF605CDD-9C75-4E63-B18B-1A6009E403C4Q34070683-C51067CE-4FB0-4116-98BE-9ED08517CE68Q35634752-0B027AC5-5F32-426E-B891-3D6D89D04AB7Q35836140-97F53EF1-4F45-4EE2-A2C6-FEA3DF6CCCFBQ36440093-DB6A162D-A44A-48AC-84FE-28BFB924F71CQ36945838-8D3DD0B9-2E57-44AC-A6CD-20F264D20EEFQ37290114-9759802F-C19B-4D81-82F5-1D3A95DB7D3FQ37940637-3ABE7E0A-3B00-49CD-90B6-FCA167ADC708Q38047778-302A65CC-EBBF-4C8A-AE02-015921277076Q38048367-A39A26A7-B449-4AE1-8CDF-D14DC3639EE1Q38461061-BA971D50-F9EE-452E-85E3-A06E037039FEQ38883770-2D3518AD-CB17-45CC-A517-443283F30940Q38949322-C41DE585-34E8-4012-8798-6EAF8C960E4DQ39384289-D70A23B9-A150-4A2E-862F-C94092EAC4E5Q39516830-EE82C5D2-421C-4EED-B9F7-1A41D9762C69Q41735508-EE0F1FD3-62A2-4D96-93A1-263A030E5255Q43170567-186CFEDE-9236-4084-8AD5-B88866034E23Q47170879-53E59AAA-29C7-4B43-834A-BCFA32DE4011Q52714689-1614D1DE-79FD-4FF0-A169-818693BE8DA6Q53646238-75BBDBFE-82E5-4AB5-A0A8-8DCD93D25CCAQ55399721-11F6B4E7-5954-438C-89E1-C9D05BEFA5A5
P2860
The bacterial second messenger cdiGMP exhibits promising activity as a mucosal adjuvant.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The bacterial second messenger cdiGMP exhibits promising activity as a mucosal adjuvant.
@ast
The bacterial second messenger cdiGMP exhibits promising activity as a mucosal adjuvant.
@en
type
label
The bacterial second messenger cdiGMP exhibits promising activity as a mucosal adjuvant.
@ast
The bacterial second messenger cdiGMP exhibits promising activity as a mucosal adjuvant.
@en
prefLabel
The bacterial second messenger cdiGMP exhibits promising activity as a mucosal adjuvant.
@ast
The bacterial second messenger cdiGMP exhibits promising activity as a mucosal adjuvant.
@en
P2093
P2860
P356
P1476
The bacterial second messenger cdiGMP exhibits promising activity as a mucosal adjuvant.
@en
P2093
Carlos A Guzmán
Kai Schulze
Michael Morr
Peggy Riese
Thomas Ebensen
P2860
P304
P356
10.1128/CVI.00119-07
P577
2007-06-13T00:00:00Z